According to filings with the U.S. Securities and Exchange Commission, Duo Oncology is raising $4,175,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Sam Rothstein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Duo Oncology
Right now, 60-80% of patients show little response to standard immunotherapy or chemotherapy. Duo Oncology plans to transform patient outcomes with a new type of nanotherapy. At Duo Oncology, we have brought together practicing clinical oncologists and diverse pharmaceutical scientists to develop simple, elegant nanomedicines for patients with cancer. We streamline operations with a team of select, globally recognized experts who are efficiently guiding our nanomedicines through the complex drug approval process to quickly reach patients. Our goal is to reinvigorate the treatment landscape for difficult-to-target tumors that are surrounded by dense stromal tissue. We mimic the self-assembly of DNA to create unprecedentedly small nanomedicines, each containing a duo of anti-cancer therapies, that can extravasate deep within tumors. Unique conditions within the tumor microenvironment cleave the environmentally sensitive bonds of our nanomedicines, releasing therapy directly in the tumor – exactly where it needs to be.

To learn more about Duo Oncology, visit http://www.duooncology.com/

Contact:
Sam Rothstein, President and Chief Executive Officer
412-246-8911
https://www.linkedin.com/in/sam-n-rothstein/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.